I am a research fellow at Harvard Medical School. My research has shown the benefits of iFR and MSCT in challenging coronary lesions. Moreover, it showed the equal efficacy of TAVR to SAVR in low-to-moderate risk patients with aortic stenosis and worked on optimizing valve selection. Further, we assessed the burden of cardiac tumors and showed the value of new therapeutics in preventing chemotherapy-induced cardiotoxicity. My research was cited in >10 International guidelines & drug updates.